Key result
Oral factor Xa inhibitors appear well tolerated without bleeding events in compensated cirrhosis and PVT.
Why the study?
Cirrhosis patients are typically excluded from anticoagulant clinical trials, leaving uncertainty about the safety and efficacy of oral factor Xa inhibitors in this population.
Are oral factor Xa inhibitors safe and effective for treating portal vein thrombosis in patients with compensated cirrhosis?
Comparison
Oral factor Xa inhibitors (rivaroxaban and apixaban)
Design
Case series reported in a letter
Follow-up
1 to 7 months
Authors
Loading...
May support oral factor Xa inhibitors for portal vein thrombosis in compensated cirrhosis; leaves open confirmation in prospective trials.
Are oral factor Xa inhibitors safe and effective for treating portal vein thrombosis in patients with compensated cirrhosis?
Oral factor Xa inhibitors may be a feasible and well-tolerated option for treating portal vein thrombosis in patients with compensated cirrhosis, though prospective studies are needed.
Intagliata et al. (2014) conducted a letter in Cirrhosis with portal vein thrombosis (n=5). Oral factor Xa inhibitors (rivaroxaban and apixaban) was evaluated on Resolution of portal vein thrombosis and bleeding events. In a series of 5 patients with compensated cirrhosis and portal vein thrombosis, treatment with oral factor Xa inhibitors was well tolerated with no bleeding events reported.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: